Histone deacetylase inhibitors for treatment of hepatocellular carcinoma

作     者：Danila CORADINI Annalisa SPERANZA 

作者机构：UO Tumor Biology and Experimental Therapy Department of Experimental Oncology Istituto Nazionale per lo Studio e la Cura dei Tumori 20133 Milan Italy UO Tumor Biology and Experimental Therapy Department of Experimental Oncology Istituto Nazionale per lo Studio e la Cura dei Tumori 20133 Milan Italy 

出 版 物：《Acta Pharmacologica Sinica》 (中国药理学报(英文版))

年 卷 期：2005年第26卷第9期

页      面：1025-1033页

核心收录：

学科分类：1007[医学-药学(可授医学、理学学位)] 1002[医学-临床医学] 100214[医学-肿瘤学] 10[医学] 

主　　题：hepatocellular carcinoma histone deace-tylase inhibitors cancer therapy 

摘      要：Hepatocellular carcinoma(HCC)is one of the most common cancers in the *** resection has been considered the optimal treatment approach,but onlya small proportion of patients are suitable candidates for surgery,and the relapserate is *** to prevent recurrence,including chemoemboliza-tionbefore and adjuvant therapy after surgery,have proven to have a limited benefit;liver transplantation is successful in treating limited-stage HCC because only aminority of patients qualify for ***,new therapeutic strat-egies are urgently *** in addition to the classical genetic mecha-nisms of deletion or inactivating point mutations,epigenetic alterations,such ashyperacetylation of the chromatin-associated histones(responsible for genesilencing),are believed to be involved in the development and progression ofHCC,novel compounds endowed with a histone deacetylase(HDAC)inhibitoryactivity are an attractive therapeutic *** particular,pre-clinical resultsobtained using HA-But,an HDAC inhibitor in which butyric acid residues areesterified to a hyaluronic acid backbone and characterized by a high affinity forthe membrane receptor CD44,indicated that this class of compounds may repre-sent a promising approach for hepatocellular carcinoma treatment.